Additional Supporting Information may be found in the online version of this article.

HEP_23089_sm_SupFig1.tif3731KSupplementary Figure 1. Generation of bsep−/−/mdr1a−/−/b−/− (TKO) mice: A. Crossing scheme. The mdr1a−/−/b−/− double knockout and bsep−/− mice were used to generate triply heterozygotic bsep+/−/ mdr1a+/−/b+/− mice (100% of offspring are triple heterozygotes). The triple heterozygotes were used to produce bsep+/−/mdr1a−/−/b−/− mice (approximately 1/8 of the offspring since the mdr1a and mdr1b genes in mice are closely linked), which were then used to generate the TKO homozygotes (bsep−/−/mdr1a−/−/b−/−). B. A PCR screening result for the TKO mice. #1, #5 and #6 are triple knockout mice, from which only bands from mutant alleles were amplified.
HEP_23089_sm_SupFig2.tif3731KSupplementary Figure 2. A. The major alternatively spliced Mdr1b transcript in the TKO mice. This transcript has an exon 4 deletion and results in translation of only 38 original Mdr1b amino acids followed by a frame shift, 6 novel amino acids and a premature stop codon. B. The minor Mdr1b transcript in TKO mice. This transcript has a deletion of exons 4, 5, and 6 that results in translation of 38 original amino acids followed by a frame shift, 12 novel amino acids and a premature stop codon. C. Western blotting of the adrenal glands from mdr1a−/−/b−/−, bsep−/−/mdr1a−/−/b−/− (TKO) and wild-type (WT) mice, showing the null expression of Mdr1b in TKO mice by loss of C219 antibody staining.
HEP_23089_sm_SupFig3.tif15401KSupplementary Figure 3. Liver hemorrhage seen in a dying TKO male at the age of 50 days. A dark red blood clot can be seen in the liver.
HEP_23089_sm_SupFig4.tif4058KSupplementary Figure 4. Western blotting of the apoptosis-related proteins Caspase-3, Bax, Bcl-2 and phosphor-Bad (Ser112) in the livers of triple knockout (bsep−/−/mdr1a−/−/b−/− TKO) mice in comparison with bsep−/−, mdr1a−/−/b−/− and wild-type mice. Equal amounts of liver lysate from individual animals were resolved by SDS-PAGE and analyzed by Western blotting using specific antibodies. The blots were re-probed with anti-β -actin antibody to confirm protein loading. Primary antibodies (anti-Caspase 3 Cat# 9662, anti-Bcl 2 Cat#2876, anti-Bax Cat#2772 and anti-Phospho-Bad (Ser112) Cat#9291) were all from Cell Signaling Technology, Inc. (Beverly, MA).

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.